MTRG Publications
MTRG researchers regularly publish journal articles and policy reports on issues related to medical technology policy, regulation and assessment.
Publications
- Main, C., Schäfer, C. & Kanavos, P. (2025). From Vision to Reality: The EU’s Pharmaceutical Reforms and the Path to Improved Access. Pharmacoeconomics - Open.
- Kanavos, P., Visintin, E. & Angelis, A. (2024). Use of the ESMO-Magnitude of Clinical Benefit Scale to guide HTA recommendations on coverage and reimbursement for cancer medicines: a retrospective analysis. The Lancet Oncology, 25 (12), 1644 - 1654
- Leon, G., Gonzalez-Pier, E., Kanavos, P., Ruiz de Castilla, E. & Machinicki, G. (2024). The 30-Billion-Dollar Distribution Markups and Taxes of Pharmaceuticals in Latin American Countries: Impact, Options, and Trade-Offs. Value in Health Regional Issues, 44, 101015.
- Leon, G., Carbonel, C., Rampuria, A., Rajpoot, R., Joshi, P. & Kanavos, P. (2024). An assessment of the implications of distribution remuneration and taxation policies on the final price of prescription medicines: evidence from 35 countries. The European Journal of Health Economics,1-24
- Augustovski, F., Colaci, C., Mills, M., Chavez, D., Argento, F., Alfie, V., Riviere, A. P., Kanavos, P., & Alcaraz, A. (2024).A Systematic Review of Value Criteria for Next-Generation Sequencing/Comprehensive Genomic Profiling to Inform Value Framework Development.Value in Health.
- Mills, M., Kanavos, P. (2023).Healthcare Payer Perspectives on the Assessment and Pricing of Oncology Multi-Indication Products: Evidence from Nine OECD Countries. PharmacoEconomics Open, 7, 553–565.
- Fontrier, AM., Kamphuis, B. & Kanavos, P. (2023). How can health technology assessment be improved to optimise access to medicines? Results from a Delphi study in Europe. Eur J Health Econ.
- Main, C., Haig, M., Chavez, D., & Kanavos, P. (2023). Assessing the Value of Provider-Facing Digital Health Technologies Used in Chronic Disease Management: Toward a Value Framework Based on Multistakeholder Perceptions.Medical Decision Making, 44(1): 28-41.
- Angelis, A., Montibeller, G., & Kanavos, P. (2023). A structured methodology for essential medicines lists and health emergency stockpiles: Experience with the Emergency Medicines Buffer Stock in the United Kingdom.Social Science & Medicine, 337, 116236.
- Haig, M., Main, C., Chavez, D. & Kanavos, P. (2023). A Value Framework to Assess Patient-Facing Digital Health Technologies That Aim to Improve Chronic Disease Management: A Delphi Approach. Value in Health , 26(10), 1474-1484.
- Apostolou, E. A., Fontrier, A., Efthimiadis, G. K., Kastritis, E., Parissis, J., & Kanavos, P. (2023). The patient pathway in ATTR-CM in Greece and how to improve it: A multidisciplinary perspective. Hellenic Journal of Cardiology, 73, 73-80.
- Kanavos, P., & Vandoros, S. (2023). Road traffic mortality and economic uncertainty: Evidence from the United States. Social Science & Medicine, 326, 115891.
- Kanavos, P., Visintin, E., & Gentilini, A. (2023).Algorithms and heuristics of health technology assessments: A retrospective analysis of factors associated with HTA outcomes for new drugs across seven OECD countries.Social Science & Medicine, 331, 116045.
- Mills, M.(2023).HTA Barriers for Conditional Approval Drugs.PharmacoEconomics, 41(5): 529-545.
- Mills M, Michaeli D, Miracolo A, Kanavos P. (2023). Launch sequencing of pharmaceuticals with multiple therapeutic indications: evidence from seven countries. BMC Health Services Research, 23, 150.
- Kamphuis, B. W. & Kanavos, P. (2021). Assessing pricing and reimbursement policies for generic pharmaceuticals in the MENA region for improved efficiency, affordability and generic penetration. Health Policy OPEN 2, 100045.
- Efthymiadou, O. & Kanavos, P. (2021). Determinants of Managed Entry Agreements in the context of Health Technology Assessment: a comparative analysis of oncology therapies in four countries. International Journal of Technology Assessment in Health Care, 37(1), e31.
- Mills, M., & Kanavos, P. (2020). Do pharmaceutical budgets deliver financial sustainability in healthcare? Evidence from Europe. Health Policy, 124(3), 239–251.
- Angelis, A., Kanavos, P. & Philips L.D. (2020). ICER Value Framework 2020 Update: recommendations on the aggregation of benefits and contextual considerations, Value in Health 23 (8), 1040 1048.
- Kanavos, P., Fontrier, A-M., Gill, J. & Efthymiadou, O. (2020). Does external reference pricing deliver what it promises? Evidence on its impact at national level. The European Journal of Health Economics, 21(1), 129–151.
- Kanavos, P., Kamphuis, B.W., Fontrier A-M., Colville Parkin, G., Saleh, S. & Ahkras, K.S. (2020). Pricing of in-patent pharmaceuticals in the Middle East and North Africa: Is external reference pricing implemented optimally?Health Policy, 124(12), 1297–1309.
- Miracolo, A., Sophiea, M., Mills, M. & Kanavos, P. (2020). The impact of sin taxes on consumption, revenue generation and health improvement: A systematic literature review in Latin America. Health Policy and Planning, 36(5), 790–810
- Fontrier, A.M., Gill, J. & Kanavos, P. (2019). International impact of external reference pricing: should national policy-makers care?. The European Journal of Health Economics, 20(8), pp.1147-1164.
- Gill, J., Fontrier, A.-M., Kyriopoulos, D., & Kanavos, P. (2019). Variations in external reference pricing implementation: Does it matter for public policy?The European Journal of Health Economics, 20(9), 1375–1397.
- Kanavos, P., Angelis, A., & Drummond, M. (2019). An EU-wide approach to HTA: An irrelevant development or an opportunity not to be missed?.The European journal of health economics : HEPAC : health economics in prevention and care, 20(3), 329–332.
- Visintin, E., Tinelli, M., & Kanavos, P. (2019). Value assessment of disease-modifying therapies for Relapsing-Remitting Multiple Sclerosis: HTA evidence from seven OECD countries.Health Policy, 123(2), 118–129.
- Angelis, A., Lange, A. & Kanavos, P. (2018). Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European countries. The European Journal of Health Economics, 19(1), 123–152.
- Efthymiadou, O., Mossman, J. & Kanavos, P. (2018). Health Related Quality of Life aspects not captured by EQ- 5D-5L: Results from an international survey of patients. Health Policy. 123(2):159-165. .
- Efthymiadou, O., Kanavos, P. & Mossman, J. (2018). Differentiation of Health-Related Quality of Life outcomes between five disease areas; results from an international survey of patients. International Journal of Technology Assessment in Health Care, 34(5), 498–506.
- Tinelli, M., Kanavos, P., Efthymiadou, O., Visintin, E., Grimaccia, F. & Mossman, J. (2018). Using IMPrESS to guide policy change in multiple sclerosis. Multiple Sclerosis. 24(9), 1251–1255.
- Gill, J., Baiceanu, A., Clark, P. J., Langford, A., Latiff, J., Yang, P.-M., Yoshida, E. M., & Kanavos, P. (2018). Insights into the hepatocellular carcinoma patient journey: Results of the first global quality of life survey. Future Oncology, 14(17), 1701–1710.
- Angelis, A., Montibeller, G., Hochhauser, D. & Kanavos P. (2017). Multiple criteria decision analysis in the context of health technology assessment: a simulation exercise on metastatic colorectal cancer with multiple stakeholders in the English setting. BMC Medical Informatics and Decision Making, 17, 149.
- Angelis, A., & Kanavos, P. (2017). Multiple Criteria Decision Analysis (MCDA) for evaluating new medicines in Health Technology Assessment and beyond: The Advance Value Framework. Social Science & Medicine, 188, 137–156.
- Angelis, A., Tordrup, D. & Kanavos, P. (2017). Is the funding of public national health systems sustainable over the long term? Evidence from eight OECD countries. Global Policy, 8(S2), 7–22.
- Gill, J., & Kanavos, P. (2017). RWE in Europe – An Analysis. Journal of Health Policy and Outcomes Research, 2/2017.
Blogs
- Europe's Beating Cancer Plan: shifting the dial in oncology policy? A blog by Dr Jennifer Gill, George Wharton and Mackenzie Mills (2023)